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ever, data on the use of drugs for nonindicatedABSTRACT
Background: Atypical antipsychotics are indicated
for speciﬁc psychiatric conditions; however, they are
frequently used for US Food and Drug Administra-
tion–nonapproved indications.
Objective: This study assessed the types of medical
diagnoses associated with atypical antipsychotic pre-
scriptions in commercial health care plans.
Methods: This retrospective cohort study used the
OptumInsight commercial data set from January 2008
to June 2011. The index date was deﬁned as the earliest
date of prescription for the atypical antipsychotics
aripiprazole, olanzapine, quetiapine, risperidone, and
ziprasidone, from January 1, 2009, through June 30,
2010. Medical claims during a 2-year period (12 months
before and 12 months after the index date) were used to
identify relevant diagnostic codes from the International
Classiﬁcation of Diseases, Ninth Edition, Clinical Mod-
iﬁcation associated with the antipsychotic prescription.
A logistic regression analysis was conducted to examine
the predictors of use of atypical antipsychotics without a
relevant diagnosis, that is, schizophrenia, bipolar, or
major depressive disorder (MDD).
Results: Of 18,352 patients included in the analysis,
3593 (19.5%) who ﬁlled a prescription for atypical
antipsychotics did not have an approved diagnosis.
Off-label utilization varied, with approximately a
quarter of patients with prescriptions for quetiapine
(24.1%), risperidone (23.1%), or olanzapine (21.8%)
being without a relevant diagnostic code, whereas pro-
portions were lower for patients prescribed aripiprazole
(14.0%) or ziprasidone (13.1%). Of those with a
psychiatric disorder other than schizophrenia, bipolar*Current afﬁliation: Boehringer Ingelheim, Ridgeﬁeld,
Connecticut.
†Current afﬁliation: AbbVie, North Chicago, Illinois.
December 2013disorder, or MDD, approximately a third of prescrip-
tions were for anxiety disorders, with similar propor-
tions across all atypical antipsychotics. Patients were
often prescribed quetiapine for substance abuse
(22.7%), whereas patients with “other psychiatric con-
ditions” were prescribed risperidone (26.3%) or zipra-
sidone (25.0%). The logistic regression analysis indi-
cated that patients prescribed olanzapine, quetiapine,
or risperidone were signiﬁcantly more likely to have no
diagnostic code for schizophrenia, bipolar disorder, or
MDD compared with patients prescribed aripiprazole.
Conclusion: Nearly a ﬁfth of commercially insured
patients were prescribed atypical antipsychotics, in partic-
ular, olanzapine, quetiapine, or risperidone, for diagnoses
that were not aligned with US Food and Drug Admin-
istration–approved indications. (Clin Ther. 2013;35:
1867–1875)
& 2013 The Authors. Published by Elsevier, Inc.
Key words: atypical antipsychotic, medical claims,
Open access under CC BY-NC-ND license. INTRODUCTION
Drugs are sometimes prescribed for US Food and
Drug Administration (FDA)-nonindicated purposes
(ie, “off-label”), which has the potential to impact
the pharmacy budget for speciﬁc conditions. How-Accepted for publication September 9, 2013.
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Clinical Therapeuticspurposes are often lacking, and variations in prescrip-
tions across similar drug classes remain largely un-
known. With regard to the use of ﬁrst-line atypical
antipsychotic medications in adults, FDA-approved
indications include schizophrenia, bipolar disorder,
and major depressive disorder (MDD), but not all
atypical antipsychotic agents have been approved for
all of these indications (Table I).1–6Table I. FDA-approved indications for atypical antipsych
Atypical Antipsychotic
Agent
Aripiprazole1 Treatment of schizophrenia; acute
bipolar I disorder as monothera
maintenance treatment of bipol
to lithium or valproate; adjunc
associated with schizophrenia o
Olanzapine2 Treatment of schizophrenia; acute
bipolar I disorder and maintena
valproate or lithium in the trea
bipolar I disorder; treatment of
bipolar I mania (injection); trea
disorder (combination with ﬂuo
(MDD in patients who do not re
of adequate dose and duration
Quetiapine IR3 Treatment of schizophrenia; acute
disorder, both as monotherapy
monotherapy for the acute trea
disorder; maintenance treatmen
divalproex
Quetiapine XR4 Treatment of schizophrenia; acute
bipolar I disorder, both as mon
divalproex; acute treatment of d
maintenance treatment of bipo
adjunctive therapy to antidepre
Risperidone5 Treatment of schizophrenia; mono
with bipolar I disorder; adjunct
the treatment of acute manic o
Ziprasidone6 Treatment of schizophrenia; mono
episodes associated with bipola
maintenance treatment of bipo
schizophrenic patients for whom
need intramuscular antipsychoti
FDA ¼ Food and Drug Administration; IR ¼ immediate release;
1868In a 2003 analysis of Medicaid fees for service in 42
states, 57.6% of patients who were prescribed atypical
antipsychotics did not have a diagnosis of schizophre-
nia or bipolar disorder.7 Similarly, in a study
analyzing data from the Veterans’ Administration
(VA) health care system in 2007, it was shown that
60.2% of patients who had a prescription for an
antipsychotic medication did not have a diagnosis ofotic agents in adults.
Indication
treatment of manic or mixed episodes associated with
py and as an adjunct to lithium or valproate;
ar I disorder, both as monotherapy and as an adjunct
tive treatment of MDD; acute treatment of agitation
r bipolar I disorder (injection)
treatment of manic or mixed episodes associated with
nce treatment of bipolar I disorder; adjunct to
tment of manic or mixed episodes associated with
acute agitation associated with schizophrenia and
tment of depressive episodes associated with bipolar I
xetine); treatment of treatment-resistant depression
spond to 2 separate trials of different antidepressants
in the current episode [combination with ﬂuoxetine])
treatment of manic episodes associated with bipolar I
and as an adjunct to either lithium or divalproex;
tment of depressive episodes associated with bipolar
t of bipolar I disorder, as an adjunct to lithium or
treatment of manic or mixed episodes associated with
otherapy and as an adjunct to either lithium or
epressive episodes associated with bipolar disorder;
lar I disorder, as an adjunct to lithium or divalproex;
ssants for the treatment of MDD
therapy for acute manic or mixed episodes associated
ive therapy with lithium or valproate is indicated for
r mixed episodes associated with bipolar I disorder
therapy for the acute treatment of manic or mixed
r I disorder; adjunct to lithium or valproate for the
lar I disorder; treatment of acute agitation in
treatment with ziprasidone is appropriate and who
c medication for rapid control of agitation (injection)
MDD ¼ major depressive disorder; XR ¼ extended release.
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L. Citrome et al.either schizophrenia or bipolar disorder.8 The most
common off-label diagnoses reported by Leslie et al8
were posttraumatic stress disorder (41.8%), minor
depression (39.5%), major depression (23.4%), and
anxiety disorder (20.0%). A recent analysis by the
Agency for Healthcare Research and Quality9 reported
that diagnoses of attention-deﬁcit/hyperactivity disorder,
anxiety, dementia in elderly patients, depression, eating
disorders, insomnia, obsessive-compulsive disorder, per-
sonality disorder, posttraumatic stress disorder, sub-
stance abuse disorders, and Tourette’s syndrome were
treated with atypical antipsychotics despite varying
evidence of efﬁcacy in the literature.
There is paucity of data describing indicated and
nonindicated use of atypical antipsychotics in com-
mercially insured patients. Therefore, the current
study explored the association between medical diag-
noses and atypical antipsychotic usage in a commer-
cial insurance database.
PATIENTS AND METHODS
Study Design and Methods
This retrospective cohort study used the OptumInsight
commercial data set from January 2008 to June 2011.
This research database represents a geographically div-
erse, national health plan and included 420 million
members during the study period. The database contains
medical (inpatient and outpatient) and prescription
claims and also a subset of laboratory results. Medical
claims were collected for all types of provided services,
and the diagnoses were coded with the International
Classiﬁcation of Diseases, Ninth Revision—Clinical
Modiﬁcation (ICD-9-CM). Pharmacy claims were re-
corded for all outpatient pharmacy services covered by
the health plan and were coded with National Drug
Codes, with detailed information, including drug name,
ﬁll date, number of days of supply, quantity (number of
pills), and drug strength. The index date was deﬁned as
the earliest date of prescription for aripiprazole, olanza-
pine, quetiapine, risperidone, or ziprasidone from Jan-
uary 1, 2009, through June 30, 2010. Medical claims
during a 2-year period (12 months before and 12 months
after the index date) were used to identify ICD-9-CM
diagnostic codes associated with the prescriptions.
Outcome Variables and Measures
The main objective of this analysis was to examine
the proportion of patients with speciﬁc diagnostic codes
for each of the 5 most commonly used ﬁrst-line second-December 2013generation antipsychotics (aripiprazole, olanzapine,
quetiapine, risperidone, and ziprasidone). The relevant
diagnostic codes included primary or secondary ICD-9-
CM diagnostic codes associated with schizophrenia
(ICD-9-CM code 295.xx), bipolar disorder (296.0x,
296.1x, 296.4x–296.9x), or MDD (296.2x, 296.3x,
311.xx) were assessed (referred to herein as relevant
diagnostic codes). For patients with 41 diagnostic
code for 1 of the above conditions, a hierarchy was
used in which patients with Z1 diagnostic code for
schizophrenia were assigned to the schizophrenia
group, and patients with codes for both bipolar and
MDD were classiﬁed in the bipolar cohort. Patients
with diagnostic codes for only 1 of these 3 diagnoses
were categorized in the corresponding cohort. If pa-
tients had none of the above diagnoses, they were
grouped into a “no diagnostic code” (ie, no diagnostic
code for schizophrenia, bipolar disorder, or MDD).
These patients were then further divided according to
whether they had diagnostic codes for “psychiatric
conditions” (ICD-9-CM codes 290.xx through 319.xx,
excluding the codes for schizophrenia, bipolar disorder,
depression) or “no psychiatric condition.” Age was
calculated based on the index date of prescription.
Patients were classiﬁed into 4 regions based on US
census (Northeast, Midwest, South, and West).
Main Inclusion/Exclusion Criteria
Patients aged 18 to 64 years with continuous
eligibility in the 12 months pre- and postindex period
of prescriptions were included. Patients using 41
atypical antipsychotic during the period were ex-
cluded. Children and adolescents were excluded be-
cause not all atypical antipsychotic agents have
received approval for use in these age categories.
Adults over the age of 64 years were excluded due
to the complexities associated with use of atypical
antipsychotic agents in elderly patients with dementia-
related psychosis, an indication for which antipsy-
chotic agents have not been approved, and for which a
“black box” warning explicitly states an increased
risk in mortality with exposure to antipsychotics in
this patient population. Possible lack of comprehen-
sive claims data for Medicare-eligible patients also led
to the exclusion of patients464 years from this study.
Statistical Analyses
Descriptive statistics were used to estimate the dis-
tribution of diagnoses for each atypical antipsychotic.1869
Clinical TherapeuticsA logistic regression analysis was conducted to examine
the predictors of use of atypical antipsychotics without a
relevant diagnosis (schizophrenia, bipolar disorder, or
MDD). Age, sex, year of index prescription, geographic
location, and type of atypical antipsychotic were exam-
ined in the regression model. These factors were selected
based on literature and availability of relevant informa-
tion in the claims database. In patients with none of the
relevant diagnostic codes, descriptive statistics were used
to identify the 5 most common psychiatric diagnostic
codes associated with each atypical antipsychotic. All
analyses were conducted using SAS version 9.1 (SAS
Institute Inc, Cary, North Carolina).Sensitivity Analysis
The exclusion criteria “patients using more than 1
atypical antipsychotic during the period” led to attri-
tion of 17% of patients. Therefore, a sensitivity
analysis was performed on the data set with this cohortTable II. Demographic characteristics of all eligible p
number (%) of patients.
Characteristic
Aripiprazole
(n ¼ 7164)
O
(
Age, mean (SD) 43.0 (12.7) 4
Female 4891 (68.3)
Index year
2009 4365 (60.9)
2010 2799 (39.1)
Region
Northeast 739 (10.3)
Midwest 1787 (24.9)
South 3675 (51.3)
West 963 (13.4)
Diagnosis group
Schizophrenia 83 (1.2)
Bipolar disorder 2279 (31.8)
MDD 3796 (53.0)
Other or no diagnostic code 1006 (14.0)
Other psychiatric conditions included
within “other or no diagnostic code”
No 358 (35.6)
Yes 648 (64.4)
MDD ¼ major depressive disorder.
1870included. In a second sensitivity analysis, the identi-
ﬁcation period for diagnosis was reduced from 24
months (12 months pre- and 12 months postindex) to
12 months (6 months pre- and 6 months postindex).RESULTS
Demographic characteristics and distribution of diag-
noses for the study population are summarized by index
antipsychotic in Table II. Slightly more than half of the
patients were female, with a mean age range of 39.4 to
43.0 years. The majority of patients in the sample
(50.0%–56.8%) were from the southern region of
the United States. Of 18,352 patients included in the
analysis, 3593 (19.6%) who ﬁlled a prescription for
atypical antipsychotics did not have a diagnostic code
for schizophrenia, bipolar disorder, or MDD. Utili-
zation varied across atypical antipsychotics, with
approximately one quarter of patients with prescrip-
tions for quetiapine (24.1% [1772/7360]), risperidoneatients by index atypical antipsychotic. Values are
lanzapine
n ¼ 1420)
Quetiapine
(n ¼ 7360)
Risperidone
(n ¼ 1903)
Ziprasidone
(n ¼ 505)
2.2 (13.0) 41.4 (12.9) 40.1 (13.8) 39.4 (13.3)
760 (53.5) 4230 (57.5) 1007 (52.9) 341 (67.5)
871 (61.3) 4404 (59.8) 1095 (57.4) 307 (60.8)
549 (38.7) 2956 (40.2) 808 (42.6) 198 (39.2)
131 (9.2) 836 (11.4) 242 (12.7) 37 (7.3)
321 (22.6) 1706 (23.2) 416 (21.9) 115 (22.8)
744 (52.4) 3740 (50.8) 952 (50.0) 287 (56.8)
224 (15.8) 1078 (14.6) 293 (15.4) 66 (13.1)
65 (4.6) 92 (1.3) 126 (6.6) 30 (5.9)
485 (34.2) 2417 (32.8) 676 (35.5) 258 (51.1)
561 (39.5) 3079 (41.8) 661 (34.7) 151 (29.9)
309 (21.8) 1772 (24.1) 440 (23.1) 66 (13.1)
101 (32.7) 501 (28.3) 105 (23.9) 18 (27.3)
208 (67.3) 1271 (71.7) 335 (76.1) 48 (72.7)
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Table III. Use of atypical antipsychotic agents for “other or no diagnostic code.” Values are number (%) of
patients.
Characteristic
Aripiprazole
(n ¼ 7164)
Olanzapine
(n ¼ 1420)
Quetiapine
(n ¼ 7360)
Risperidone
(n ¼ 1903)
Ziprasidone
(n ¼ 505)
Age
18–24 y 124/850 (14.6) 37/181 (20.4) 228/1061 (21.5) 102/375 (27.2) 15/93 (16.1)
25–34 y 150/1007 (14.9) 46/247 (18.6) 255/1262 (20.2) 69/311 (22.2) 10/88 (11.4)
35–44 y 227/1741 (13.0) 73/341 (21.4) 388/1786 (21.7) 84/421 (20.0) 11/134 (8.2)
45–54 y 269/2012 (13.4) 76/352 (21.6) 503/1915 (26.3) 96/448 (21.4) 14/110 (12.7)
55–64 y 236/1554 (15.2) 77/299 (25.8) 398/1336 (29.8) 89/348 (25.6) 16/80 (20.0)
Sex
Female 559/4891 (11.4) 162/760 (21.3) 883/4230 (20.9) 193/1007 (19.2) 33/341 (9.7)
Male 447/2273 (19.7) 147/660 (22.3) 889/3130 (28.4) 247/896 (27.6) 33/164 (20.1)
Region
Northeast 120/739 (16.2) 29/131 (22.1) 180/836 (21.5) 63/242 (26.0) 5/37 (13.5)
Midwest 196/1787 (11.0) 54/321 (16.8) 328/1706 (19.2) 68/416 (16.3) 13/115 (11.3)
South 538/3675 (14.6) 183/744 (24.6) 1004/3740 (26.8) 234/952 (24.6) 42/287 (14.6)
West 152/963 (15.8) 43/224 (19.2) 260/1078 (24.1) 75/293 (25.6) 6/66 (9.1)
L. Citrome et al.(23.1% [440/1903]), or olanzapine (21.8% [309/1420])
not having a relevant diagnostic code while proportions
were lower for patients prescribed aripiprazole (14.0%
[1006/7164]) or ziprasidone (13.1% [66/505]). Al-
though risperidone and ziprasidone are not FDA-
approved for MDD, 34.7% of patients receiving risperi-
done and 29.9% of patients receiving ziprasidone had a
diagnostic code of MDD.
The patterns regarding “other or no diagnostic
code” were consistent across age group, sex, and
region (Table III). A breakdown of the types of
“psychiatric conditions” included in the “other or
no diagnostic code” category is shown in Table IV. Of
these, a third of patients were treated for anxiety
disorders with any of the antipsychotics considered.
Substance abuse was the indication observed for
22.7% of quetiapine prescriptions, whereas 26.3%
of risperidone and 25.0% of ziprasidone prescriptions
were for “other psychiatric conditions.”
A logistic regression analysis was conducted to
examine the predictors of use of atypical antipsychotics
without a diagnosis of schizophrenia, bipolar disorder,
or MDD (Table V). Women or patients residing in the
Midwest were associated with a signiﬁcantly lower
likelihood of not having a medical diagnosis of
schizophrenia, bipolar disorder, or MDD. PatientsDecember 2013receiving treatment with olanzapine, quetiapine, or
risperidone were signiﬁcantly more likely to have no
diagnostic code for these diagnoses compared with
patients prescribed aripiprazole. No differences were
observed between patients prescribed ziprasidone
versus those receiving aripiprazole.
The ﬁrst sensitivity analysis included patients with
multiple antipsychotic prescriptions in the analyzed
time frame. The patients were classiﬁed into a speciﬁc
antipsychotic cohort based on their index antipsy-
chotic. Results in this sample (n ¼ 22,706) demon-
strated a slightly lower proportion (17.4%) of atypical
antipsychotic users who did not have a diagnostic
code for schizophrenia, bipolar disorder, or MDD.
Results by type of atypical antipsychotic were con-
sistent with the main analysis, showing that a slightly
higher proportion of patients with prescriptions for
quetiapine (21.8%), risperidone (19.6%), or olanza-
pine (18.4%) did not have a relevant diagnostic code,
while lower proportions were observed for patients
using aripiprazole (12.7%) or ziprasidone (10.7%) as
their index atypical antipsychotic.
The second sensitivity analysis was conducted by
reducing the time frame for identifying the medical
diagnosis from 24 months (12 month pre- and post-
index) to 12 months (6 months pre- and postindex).1871
Table IV. Psychiatric conditions included in the “other or no diagnostic code” by index atypical antipsychotic.
Values are number (%) of patients.
Condition/Code
Aripiprazole
(n ¼ 648)
Olanzapine
(n ¼ 208)
Quetiapine
(n ¼ 1271)
Risperidone
(n ¼ 335)
Ziprasidone
(n ¼ 48)
Acute reaction to stress (308.x, 309.x) 83 (12.8) 28 (13.5) 129 (10.1) 34 (10.1) 2 (4.2)
Anxiety disorders (300.0x) 215 (33.2) 71 (34.1) 460 (36.2) 90 (26.9) 13 (27.1)
Childhood attention deﬁcit disorder
(314.x)
65 (10.0) 13 (6.3) 54 (4.2) 28 (8.4) 6 (12.5)
Dysthymia (300.4x) 101 (15.6) 20 (9.6) 97 (7.6) 10 (3.0) 3 (6.3)
Obsessive-compulsive disorder (300.3x) 39 (6.0) 2 (1.0) 21 (1.7) 19 (5.7) 3 (6.3)
Sleep disorders (307.4x) 6 (0.9) 5 (2.4) 48 (3.8) 2 (0.6) 1 (2.1)
Substance abuse (291.x, 292.x,
303.x–305.x)
46 (7.1) 31 (14.9) 288 (22.7) 36 (10.7) 8 (16.7)
Unspeciﬁed psychosis (298.9x) 7 (1.1) 6 (2.9) 17 (1.3) 28 (8.4) 1 (2.1)
Other psychiatric conditions 86 (13.3) 32 (15.3) 157 (12.4) 88 (26.3) 12 (25.0)
Clinical TherapeuticsResults corroborated the outcomes seen previously,
with a slightly higher proportion of patients with
prescriptions for quetiapine (29.0%), olanzapine
(26.8%), and risperidone (25.0%) not having a
relevant diagnostic code, whereas lower proportions
were observed for patients using aripiprazole (18.7%)Table V. Logistic regression analysis.*
Variable OR (95% CI) P Value
Female vs male 0.6 (0.6–0.7) o0.001
Index year 2009 vs 2010 1.0 (0.9–1.1) 0.440
Region vs West
Northeast 1.0 (0.8–1.1) 0.558
South 1.1 (1.0–1.2) 0.230
Midwest 0.7 (0.6–0.8) o0.001
Atypical antipsychotic vs
aripiprazole
Olanzapine 1.6 (1.4–1.8) o0.001
Quetiapine 1.9 (1.7–2.0) o0.001
Risperidone 1.7 (1.5–2.0) o0.001
Ziprasidone 0.9 (0.7–1.2) 0.604
MDD ¼ major depressive disorder; OR ¼ odds ratio.
*Adjusted ORs are provided for patients with no
diagnostic code for schizophrenia, bipolar disorder,
or MDD.
1872or ziprasidone (15.2%). As the time frame for iden-
tifying medical codes was reduced in this second
sensitivity analysis, a slightly higher proportion
(24.1%) of users of atypical antipsychotic agents did
not have a diagnostic code for schizophrenia, bipolar
disorder, or MDD.DISCUSSION
The current analysis showed that nearly a ﬁfth of
patients using atypical antipsychotics in commercial
health plans had no diagnosis for schizophrenia,
bipolar disorder, or MDD. The results varied slightly
based on inclusion criteria and analytical time frames,
and sensitivity analyses indicated that the proportion
of patients without a relevant diagnostic code ranged
from 17.4% to 24.1%. In this population of commer-
cially insured persons, most patients receiving a
prescription for an atypical antipsychotic had a
diagnosis of bipolar disorder or MDD, with relatively
few cases of schizophrenia in this data set. MDD
accounted for a signiﬁcant proportion of prescriptions
for all atypical antipsychotics, including approxi-
mately a third of risperidone and ziprasidone pre-
scriptions, despite neither of these having an
indication for MDD during the study period. Overall,
for patients with no diagnostic code for schizophrenia,
bipolar disorder, or MDD, the predominant diagnostic
codes observed were for anxiety disorder and substance
abuse disorder. Aripiprazole and ziprasidone had theVolume 35 Number 12
L. Citrome et al.lowest use of any of the atypical antipsychotics for
diagnoses outside schizophrenia, bipolar disorder,
and MDD.
Previous evidence from the VA health care sys-
tems showed that 60.2% of veterans who had a
prescription for an antipsychotic medication did not
have a diagnosis of either schizophrenia or bipolar
disorder in the same year.8 This was consistent with
a Medicaid assessment of medical claims data in
2004, in which only 15% of a cohort of 830 patients
who began treatment with antipsychotics had a
documented diagnosis of schizophrenia.10 Patients
in the latter analysis who had no diagnostic code
were prescribed antipsychotics primarily for the
treatment of anxiety disorders or substance abuse
disorders.
The results from our study demonstrated a lower
utilization of atypical antipsychotics for nonapproved
indications compared with previous estimates. This
difference could be largely the result of differences in
patient types. Our estimates were based on commer-
cially insured patients, whereas previous studies were
of patients enrolled in Medicaid or VA health care
systems. The use of more recent analytical time
periods (2009–2011) in our study, along with the
inclusion of MDD as a valid diagnostic code, could
also have led to lower off-label utilization in our
study. It is also important to note that estimates from
the literature suggest that off-label prescriptions are
more prevalent among individuals under the age of 21
years (75.9%) or over 65 years (64.8%) than among
those aged 21 to 64 years (49.0%).7 Our analysis
was restricted to patients aged 18 to 64 years and thus
may have underestimated nonapproved indication
use among the larger population of users of atypical
antipsychotics. It should also be noted that the app-
roved indications for the different atypical anti-
psychotics are not uniform (eg, risperidone and
ziprasidone are not FDA-approved for MDD). In
addition, the diagnostic codes did not differentiate
between subclassiﬁcations of bipolar disorder, such as
bipolar depression, in which approvals also differ.
Thus, our ﬁndings reﬂect prescriptions for use in
psychiatric conditions for which the atypical anti-
psychotics are not approved (relevant diagnosis use)
rather than a strict assessment of off-label use.
Consistent with previously published data, our
results indicate that women were more likely than
men to be prescribed atypical antipsychotics for anDecember 2013“on-label” diagnosis.11 The current study did not
explore racial or ethnic differences because such
information was not available from the analyzed
data set. However, previous estimates have shown
that off-label utilization is relatively high for His-
panics (65.7%) and low for blacks (52.3%) compared
with whites (58.2%).7
The trend toward off-label use of quetiapine for
anxiety disorders may reﬂect the availability of data
from registration trials in this population, as these
data were used by the manufacturer when seeking
FDA approval of the extended-release formulation of
quetiapine for the treatment of generalized anxiety
disorder.12 Moreover, because substance abuse disorder
is often associated with comorbid depression and/or
anxiety, the observed use of quetiapine for substance
abuse disorder may partly be a result of unrecorded
depression and/or anxiety.
Data from Medicaid and the VA suggest that the
use of atypical antipsychotics by diagnosis increases
over time (ie, time-related diffusion).13 For example,
clozapine, olanzapine, quetiapine, and risperidone
were FDA-approved for use in treating schizo-
phrenia-related psychosis between 1997 and 2000.
However, following their introduction, older medi-
cations such as typical antipsychotics had a greater
relative likelihood of use outside of schizophrenia
and psychotic disorders. Similarly, risperidone,
which was ﬁrst marketed in early 1994, had greater
relative use outside of schizophrenia and psychotic
disorders than did olanzapine, which was ﬁrst mar-
keted in late 1996. Given that the most recently
approved atypical antipsychotics in the analysis
(aripiprazole and ziprasidone) showed the lowest
proportion of off-label use, the phenomenon of
time-related diffusion could have affected the results
from the current analysis. However, this is unlikely
because the time frame for the current analysis was
7 years after the initial approval of aripiprazole
in 2002 and 8 years after the initial approval of
ziprasidone in 2001.
Our study focused only on the presence or absence of
medical diagnoses—doses of atypical antipsychotics
were not examined. Studies in the literature have
demonstrated a high prevalence of atypical antipsychotic
use in doses outside of those recommended by the FDA.
Among VA patients with mental illness other than
schizophrenia or bipolar disorder, doses were below
those recommended for schizophrenia for more than1873
Clinical Therapeuticshalf of the patients who received off-label prescriptions
for quetiapine, risperidone, or typical antipsychotics.8 A
Medicaid assessment of medical claims data in 2004 for
a cohort of 830 patients who began treatment with
antipsychotics showed that subtherapeutic dosing was
common (up to 86% for quetiapine).10
Although atypical antipsychotics have been shown
to be efﬁcacious in treating a range of psychiatric
conditions, they also have a variety of side effects. Use
of these therapies for conditions outside the recom-
mended labeled indication can potentially be a patient
safety concern and also lead to eventual budgetary
constraints for payers and society. Our results indi-
cated that the level of off-label use for atypical
antipsychotics was around 20% in patients insured
by commercial health plans. Although this is lower
than previous estimates in other patient populations, it
is high enough to have potential safety and ﬁnancial
implications. Unique to our study is the demonstration
of variation in off-label use based on the speciﬁc
atypical antipsychotic agent. Such comparative data
can be extremely useful to policymakers and plans as
they decide on formulary policies for the inclusion of
atypical antipsychotics. The inclusion of drugs with
the least potential for off-label use can provide policy-
makers with a tool for providing appropriate cost-
efﬁcient patient care in psychiatry.
There were limitations associated with this study.
The analysis was conducted using insurance claims
data; therefore, no clinical information was available
for the patients included in the analysis. In addition,
the results were limited and sensitive to the accuracy
in the selection of ICD-9-CM codes for the identiﬁca-
tion of a medical diagnosis. Miscoding in clinical
practice settings could lead to variations in estimates.
In the current analysis, codes 296.2x, 296.3x, and
311.xx were used for the identiﬁcation of MDD;
codes 296.2x and 296.3x are distinct codes for
MDD, whereas code 311.xx is “Depression—not
elsewhere classiﬁed.” However, 311.xx is one of the
most commonly used codes for depression and there-
fore is typically used in research studies for identifying
MDD from claims data. In practice, ICD-9-CM code
311 is often the only code available on a clinic’s
administrative encounter form, and therefore 311.xx
is the most commonly used code for depression in
clinical practice. Thus, the preponderance of 1 speciﬁc
ICD-9-CM code is more likely due to administrative
practice than to an inability to accurately diagnose1874depression.14 With regard to the use of atypical
antipsychotics for MDD, there is the possibility that
some of the prescriptions were for monotherapy, even
though the FDA-approved indications of aripiprazole,
quetiapine extended-release, and olanzapine for MDD
are for adjunctive use with antidepressant medication,
and for olanzapine speciﬁcally with ﬂuoxetine. Our
analysis did not address whether the off-label use of
atypical antipsychotics is clinically useful. There is the
possibility that the evidence base may support some
off-label use. Finally, it is important to note that the
current study did not explore the use of atypical
antipsychotics for nonpsychiatric diagnoses, which is
an area that merits further analysis.
CONCLUSIONS
Nearly a ﬁfth of commercially insured patients ﬁlling a
prescription for atypical antipsychotics did not have a
diagnostic code for schizophrenia, bipolar disorder, or
MDD. Off-label utilization varied across atypical
antipsychotics, with a higher proportion of patients
prescribed olanzapine, quetiapine, or risperidone not
having a relevant diagnostic code compared with
patients prescribed aripiprazole or ziprasidone.
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